Cargando…

Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence

Activated phosphoinositide 3-kinase delta syndrome (APDS), caused by mutations in PI3Kδ catalytic p110δ (PIK3CD) or regulatory p85α (PIK3R1) subunits, is a primary immunodeficiency affecting both humoral and cellular immunity, which shares some phenotypic similarities with hyper-IgM syndromes and co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloomfield, Marketa, Klocperk, Adam, Zachova, Radana, Milota, Tomas, Kanderova, Veronika, Sediva, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326455/
https://www.ncbi.nlm.nih.gov/pubmed/34350147
http://dx.doi.org/10.3389/fped.2021.697706
_version_ 1783731823987130368
author Bloomfield, Marketa
Klocperk, Adam
Zachova, Radana
Milota, Tomas
Kanderova, Veronika
Sediva, Anna
author_facet Bloomfield, Marketa
Klocperk, Adam
Zachova, Radana
Milota, Tomas
Kanderova, Veronika
Sediva, Anna
author_sort Bloomfield, Marketa
collection PubMed
description Activated phosphoinositide 3-kinase delta syndrome (APDS), caused by mutations in PI3Kδ catalytic p110δ (PIK3CD) or regulatory p85α (PIK3R1) subunits, is a primary immunodeficiency affecting both humoral and cellular immunity, which shares some phenotypic similarities with hyper-IgM syndromes and common variable immunodeficiency (CVID). Since its first description in 2013, over 200 patients have been reported worldwide. Unsurprisingly, many of the newly diagnosed patients were recruited later in life from previously long-standing unclassified immunodeficiencies and the early course of the disease is, therefore, often less well-described. In this study, we report clinical and laboratory features of eight patients followed for APDS, with particular focus on early warning signs, longitudinal development of their symptoms, individual variations, and response to therapy. The main clinical features shared by our patients included recurrent bacterial and viral respiratory tract infections, gastrointestinal disease, non-malignant lymphoproliferation, autoimmune thyroiditis, and susceptibility to EBV. All patients tolerated vaccination with both attenuated live and subunit vaccines with no adverse effects, although some failed to mount adequate antibody response. Laboratory findings were characterized by dysgammaglobulinaemia, elevated serum IgM, block in B-cell maturation with high transitional B cells, and low naïve T cells with CD8 T-cell activation. All patients benefited from immunoglobulin replacement therapy, whereas immunosuppression with mTOR pathway inhibitors was only partially successful. Therapy with specific PI3K inhibitor leniolisib was beneficial in all patients in the clinical trial. These vignettes, summary data, and particular tell-tale signs should serve to facilitate early recognition, referral, and initiation of outcome-improving therapy.
format Online
Article
Text
id pubmed-8326455
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83264552021-08-03 Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence Bloomfield, Marketa Klocperk, Adam Zachova, Radana Milota, Tomas Kanderova, Veronika Sediva, Anna Front Pediatr Pediatrics Activated phosphoinositide 3-kinase delta syndrome (APDS), caused by mutations in PI3Kδ catalytic p110δ (PIK3CD) or regulatory p85α (PIK3R1) subunits, is a primary immunodeficiency affecting both humoral and cellular immunity, which shares some phenotypic similarities with hyper-IgM syndromes and common variable immunodeficiency (CVID). Since its first description in 2013, over 200 patients have been reported worldwide. Unsurprisingly, many of the newly diagnosed patients were recruited later in life from previously long-standing unclassified immunodeficiencies and the early course of the disease is, therefore, often less well-described. In this study, we report clinical and laboratory features of eight patients followed for APDS, with particular focus on early warning signs, longitudinal development of their symptoms, individual variations, and response to therapy. The main clinical features shared by our patients included recurrent bacterial and viral respiratory tract infections, gastrointestinal disease, non-malignant lymphoproliferation, autoimmune thyroiditis, and susceptibility to EBV. All patients tolerated vaccination with both attenuated live and subunit vaccines with no adverse effects, although some failed to mount adequate antibody response. Laboratory findings were characterized by dysgammaglobulinaemia, elevated serum IgM, block in B-cell maturation with high transitional B cells, and low naïve T cells with CD8 T-cell activation. All patients benefited from immunoglobulin replacement therapy, whereas immunosuppression with mTOR pathway inhibitors was only partially successful. Therapy with specific PI3K inhibitor leniolisib was beneficial in all patients in the clinical trial. These vignettes, summary data, and particular tell-tale signs should serve to facilitate early recognition, referral, and initiation of outcome-improving therapy. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326455/ /pubmed/34350147 http://dx.doi.org/10.3389/fped.2021.697706 Text en Copyright © 2021 Bloomfield, Klocperk, Zachova, Milota, Kanderova and Sediva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Bloomfield, Marketa
Klocperk, Adam
Zachova, Radana
Milota, Tomas
Kanderova, Veronika
Sediva, Anna
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title_full Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title_fullStr Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title_full_unstemmed Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title_short Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
title_sort natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326455/
https://www.ncbi.nlm.nih.gov/pubmed/34350147
http://dx.doi.org/10.3389/fped.2021.697706
work_keys_str_mv AT bloomfieldmarketa naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence
AT klocperkadam naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence
AT zachovaradana naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence
AT milotatomas naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence
AT kanderovaveronika naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence
AT sedivaanna naturalcourseofactivatedphosphoinositide3kinasedeltasyndromeinchildhoodandadolescence